Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in relapsing MS patients switching from IV anti-CD20 therapy
NCT04486716Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Oct 2020; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04486716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486716.